Drug
Lenalidomide 25mg
Lenalidomide 25mg is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
50%(1 trials)
Phase Distribution
Ph phase_3
1
25%
Ph phase_2
2
50%
Phase Distribution
0
Early Stage
2
Mid Stage
1
Late Stage
Phase Distribution3 total trials
Phase 2Efficacy & side effects
2(66.7%)
Phase 3Large-scale testing
1(33.3%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(2)
Other(2)
Detailed Status
unknown2
Completed2
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 22 (66.7%)
Phase 31 (33.3%)
Trials by Status
unknown250%
completed250%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_3
Frontline Lenalidomide for AL Amyloidosis Involving Myocardium
NCT04298372
completedphase_2
Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma
NCT01380106
unknownphase_2
Phase II of Lenalidomide After Salvage Therapy in R/R Non-Hodgkin T-cell Lymphoma
NCT03730740
unknown
Lenalidomide Based Immunotherapy in the Treatment of DLBCL
NCT03715296
Clinical Trials (4)
Showing 4 of 4 trials
NCT04298372Phase 3
Frontline Lenalidomide for AL Amyloidosis Involving Myocardium
NCT01380106Phase 2
Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma
NCT03730740Phase 2
Phase II of Lenalidomide After Salvage Therapy in R/R Non-Hodgkin T-cell Lymphoma
NCT03715296
Lenalidomide Based Immunotherapy in the Treatment of DLBCL
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4